LOTTE BIOLOGICS Expands Global CDMO Presence with ADC Facility and Strategic Partnerships

LOTTE BIOLOGICS is making significant strides in the global Contract Development and Manufacturing Organization (CDMO) market, leveraging its dual manufacturing bases in North America and Asia, along with advancements in next-generation Antibody-Drug Conjugate (ADC) modalities.

Syracuse Bio Campus: A Hub for Advanced Biologics Manufacturing

LOTTE BIOLOGICS has completed a major expansion of its ADC facility at the Syracuse Bio Campus in New York, solidifying its position as a key player in the North American biopharmaceutical manufacturing landscape. The company has invested approximately $100 million to establish advanced ADC production infrastructure, including conjugation suites with capacities of up to 1,000L.

The newly expanded facility boasts state-of-the-art safety design, cross-contamination prevention systems, and high-efficiency production lines. These enhancements enable LOTTE BIOLOGICS to respond agilely to the growing demand for next-generation biologics while maintaining rigorous quality controls.

James Park, CEO of LOTTE BIOLOGICS, emphasized the strategic importance of the Syracuse site, stating, "The quality competitiveness and global production track record of the Syracuse facility are core assets of the company, and these capabilities are playing a key role in securing new contracts."

Technological Advancements and Strategic Partnerships

In addition to its infrastructure investments, LOTTE BIOLOGICS is advancing its technological capabilities through its proprietary ADC platform, SoluFlex Link™. This innovative technology improves linker-payload solubility and ADC hydrophilicity, enhancing drug stability and efficacy while offering flexibility for various indications.

The company's technological edge has already begun to yield results. In April, LOTTE BIOLOGICS signed its first ADC production agreement with an Asia-based biotech company for a clinical candidate, marking the official launch of its ADC CDMO partnerships.

To further enhance its CDMO capabilities, LOTTE BIOLOGICS is pursuing strategic collaborations with leading domestic and global biotech companies across various domains, including ADC platform development, cell line development, and contract development (CDO).

Global Expansion and Future Outlook

While the Syracuse campus serves as a one-stop CDMO hub for antibody and ADC production in North America, LOTTE BIOLOGICS is simultaneously developing a large-scale commercial bio campus in Songdo, South Korea. The first plant at the Songdo site is scheduled to begin operations in 2027, complementing the overall manufacturing network as a large-scale production base.

A company representative noted, "As the operational timeline for the Songdo Bio Campus becomes clearer, discussions with multiple companies for new contracts are also becoming more concrete. We're seeing increased site visits from potential clients at both the Syracuse and Songdo sites."

LOTTE BIOLOGICS continues to increase its brand awareness and engage with potential clients through participation in major global events such as the BIO International Convention, JP Morgan Healthcare Conference, CPhI Worldwide, and World ADC Summit. With its expanding capabilities and strategic global presence, LOTTE BIOLOGICS is well-positioned to capitalize on the growing demand for advanced biologics manufacturing services in the pharmaceutical industry.